{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:10:21Z","timestamp":1775610621974,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10147-025-02831-0","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:07:57Z","timestamp":1753081677000},"page":"2022-2031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine\/tipiracil plus bevacizumab in patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-8923","authenticated-orcid":false,"given":"Koshiro","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-0446","authenticated-orcid":false,"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-5775","authenticated-orcid":false,"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7547-6570","authenticated-orcid":false,"given":"Daisaku","family":"Kamiimabeppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-4486","authenticated-orcid":false,"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-8425","authenticated-orcid":false,"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3859","authenticated-orcid":false,"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-8185","authenticated-orcid":false,"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-1140","authenticated-orcid":false,"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-5709","authenticated-orcid":false,"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-5894","authenticated-orcid":false,"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"2831_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/s1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) Folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075. https:\/\/doi.org\/10.1016\/s1470-2045(14)70330-4","journal-title":"Lancet Oncol"},{"key":"2831_CR2","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392\u20132401. https:\/\/doi.org\/10.1001\/jama.2017.7105","journal-title":"JAMA"},{"key":"2831_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271\u20131282. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"JAMA"},{"key":"2831_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","volume":"22","author":"A Grothey","year":"2004","unstructured":"Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209\u20131214. https:\/\/doi.org\/10.1200\/JCO.2004.11.037","journal-title":"J Clin Oncol"},{"key":"2831_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(12)61900-x","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/s0140-6736(12)61900-x","journal-title":"Lancet"},{"key":"2831_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/nejmoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Eng J Med 372:1909\u20131919. https:\/\/doi.org\/10.1056\/nejmoa1414325","journal-title":"N Eng J Med"},{"key":"2831_CR7","first-page":"249","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Nakagawa F, Fujioka A et al (2004) An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13:249\u2013255","journal-title":"Int J Mol Med"},{"key":"2831_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3892\/ijo.17.2.277","volume":"17","author":"Y Murakami","year":"2000","unstructured":"Murakami Y, Kazuno H, Emura T et al (2000) Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 17:277\u2013283. https:\/\/doi.org\/10.3892\/ijo.17.2.277","journal-title":"Int J Oncol"},{"key":"2831_CR9","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Sakamoto K, Okabe H et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32:2319\u20132326. https:\/\/doi.org\/10.3892\/or.2014.3487","journal-title":"Oncol Rep"},{"key":"2831_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0006-2952(00)00253-7","volume":"59","author":"M Fukushima","year":"2000","unstructured":"Fukushima M, Suzuki N, Emura T et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides. Biochem Pharmacol 59:1227\u20131236. https:\/\/doi.org\/10.1016\/s0006-2952(00)00253-7","journal-title":"Biochem Pharmacol"},{"key":"2831_CR11","first-page":"571","volume":"25","author":"T Emura","year":"2004","unstructured":"Emura T, Suzuki N, Yamaguchi M et al (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25:571\u2013578","journal-title":"Int J Oncol"},{"key":"2831_CR12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Eng J Med 388:1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963","journal-title":"N Eng J Med"},{"issue":"3_suppl","key":"2831_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2024.42.3_suppl.118","volume":"42","author":"H Satake","year":"2024","unstructured":"Satake H, Yamazaki K, Suwa Y et al (2024) First report of the randomized phase III study of bi-weekly trifluridine\/tipiracil (FTD\/TPI) plus bevacizumab (BEV) vs. FTD\/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS). J Clin Oncol 42(3_suppl):118. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.118","journal-title":"J Clin Oncol"},{"key":"2831_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdx738","journal-title":"Ann Oncol"},{"key":"2831_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342. https:\/\/doi.org\/10.1007\/s10147-019-01485-z","journal-title":"Int J Clin Oncol"},{"key":"2831_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328\u2013335. https:\/\/doi.org\/10.1016\/j.bbrc.2005.05.132","journal-title":"Biochem Biophys Res Commun"},{"key":"2831_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/cam4.3638","volume":"10","author":"H Osumi","year":"2021","unstructured":"Osumi H, Shinozaki E, Ooki A et al (2021) Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer Med 10:615\u2013625. https:\/\/doi.org\/10.1002\/cam4.3638","journal-title":"Cancer Med"},{"key":"2831_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"2831_CR19","unstructured":"U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE), version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 20 April 2024"},{"key":"2831_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2831_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337. https:\/\/doi.org\/10.1016\/s1470-2045(12)70477-1","journal-title":"Lancet Oncol"},{"key":"2831_CR22","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/jci24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610\u20132621. https:\/\/doi.org\/10.1172\/jci24612","journal-title":"J Clin Invest"},{"key":"2831_CR23","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1158\/1078-0432.ccr-12-0002","volume":"18","author":"AW Griffioen","year":"2012","unstructured":"Griffioen AW, Mans LA, de Graaf AMA et al (2012) Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 18:3961\u20133971. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-0002","journal-title":"Clin Cancer Res"},{"key":"2831_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R et al (2023) Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402:41\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(23)00772-9","journal-title":"Lancet"},{"key":"2831_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/go.23.00461","volume":"10","author":"S Bazarbashi","year":"2024","unstructured":"Bazarbashi S, Alkhatib R, Aseafan M et al (2024) Efficacy of chemotherapy rechallenge versus regorafenib or trifluridine\/tipiracil in third-line setting of metastatic colorectal cancer: a multicenter retrospective comparative study. JCO Glob Oncol 10:e2300461. https:\/\/doi.org\/10.1200\/go.23.00461","journal-title":"JCO Glob Oncol"},{"key":"2831_CR26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S et al (2022) Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med 28:1612\u20131618. https:\/\/doi.org\/10.1038\/s41591-022-01886-0","journal-title":"Nat Med"},{"key":"2831_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000365156","volume":"40","author":"RA Lafayette","year":"2014","unstructured":"Lafayette RA, McCall B, Li N et al (2014) Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials. Am J Nephrol 40:75\u201383. https:\/\/doi.org\/10.1159\/000365156","journal-title":"Am J Nephrol"},{"key":"2831_CR28","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/asn.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L et al (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381\u20131389. https:\/\/doi.org\/10.1681\/asn.2010020167","journal-title":"J Am Soc Nephrol"},{"key":"2831_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP et al (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46:439\u2013448. https:\/\/doi.org\/10.1016\/j.ejca.2009.11.001","journal-title":"Eur J Cancer"},{"key":"2831_CR30","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788\u20131795","journal-title":"Br J Cancer"},{"key":"2831_CR31","first-page":"8675","volume":"7","author":"N Zhao","year":"2014","unstructured":"Zhao N, Xu Q, Wang M et al (2014) Mechanism of kidney injury caused by bevacizumab in rats. Int J Clin Exp Pathol 7:8675\u20138683","journal-title":"Int J Clin Exp Pathol"},{"key":"2831_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000360180","volume":"86","author":"SR Hayman","year":"2014","unstructured":"Hayman SR, Calle JC, Jatoi A et al (2014) Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies. Oncology 86:271\u2013278. https:\/\/doi.org\/10.1159\/000360180","journal-title":"Oncology"},{"key":"2831_CR33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s10147-023-02357-3","volume":"28","author":"S Dote","year":"2023","unstructured":"Dote S, Shiwaku E, Kohno E et al (2023) Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study. Int J Clin Oncol 28:1054\u20131062. https:\/\/doi.org\/10.1007\/s10147-023-02357-3","journal-title":"Int J Clin Oncol"},{"key":"2831_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/ol.2021.13044","volume":"22","author":"D Kamiimabeppu","year":"2021","unstructured":"Kamiimabeppu D, Osumi H, Shinozaki E et al (2021) Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine\/tipiracil plus bevacizumab. Oncol Lett 22:783","journal-title":"Oncol Lett"},{"key":"2831_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.668","volume":"35","author":"T Sakakida","year":"2024","unstructured":"Sakakida T, Masuishi T, Mitani S et al (2024) Prabitas study: a pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine\/tipiracil plus bevacizumab for refractory metastatic colorectal cancer. Ann Oncol 35:S480. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.668","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02831-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:38:16Z","timestamp":1758872296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02831-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2831"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02831-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were in accordance with the tenets of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethics review board of the Cancer Institute Hospital of the Japanese Foundation of Cancer Research (IRB number: 2020\u20101017).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study protocol was described on the hospital website and participants were provided an opportunity to opt out. No additional informed consent was obtained from the enrolled patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}